Cargando…

Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance

BACKGROUND: Estimates of the prevalence of transmitted HIV drug resistance (TDR) in a population are derived from resistance tests performed on samples from patients thought to be naïve to antiretroviral treatment (ART). Much of the debate over reliability of estimates of the prevalence of TDR has f...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Hannah, Pillay, Deenan, Sabin, Caroline, Dunn, David T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364874/
https://www.ncbi.nlm.nih.gov/pubmed/22416878
http://dx.doi.org/10.1186/1471-2288-12-30
_version_ 1782234597359091712
author Castro, Hannah
Pillay, Deenan
Sabin, Caroline
Dunn, David T
author_facet Castro, Hannah
Pillay, Deenan
Sabin, Caroline
Dunn, David T
author_sort Castro, Hannah
collection PubMed
description BACKGROUND: Estimates of the prevalence of transmitted HIV drug resistance (TDR) in a population are derived from resistance tests performed on samples from patients thought to be naïve to antiretroviral treatment (ART). Much of the debate over reliability of estimates of the prevalence of TDR has focused on whether the sample population is representative. However estimates of the prevalence of TDR will also be distorted if some ART-experienced patients are misclassified as ART-naïve. METHODS: The impact of misclassification bias on the rate of TDR was examined. We developed methods to obtain adjusted estimates of the prevalence of TDR for different misclassification rates, and conducted sensitivity analyses of trends in the prevalence of TDR over time using data from the UK HIV Drug Resistance Database. Logistic regression was used to examine trends in the prevalence of TDR over time. RESULTS: The observed rate of TDR was higher than true TDR when misclassification was present and increased as the proportion of misclassification increased. As the number of naïve patients with a resistance test relative to the number of experienced patients with a test increased, the difference between true and observed TDR decreased. The observed prevalence of TDR in the UK reached a peak of 11.3% in 2002 (odds of TDR increased by 1.10 (95% CI 1.02, 1.19, p(linear trend) = 0.02) per year 1997-2002) before decreasing to 7.0% in 2007 (odds of TDR decreased by 0.90 (95% CI 0.87, 0.94, p(linear trend) < 0.001) per year 2002-2007. Trends in adjusted TDR were altered as the misclassification rate increased; the significant downward trend between 2002-2007 was lost when the misclassification increased to over 4%. CONCLUSION: The effect of misclassification of ART on estimates of the prevalence of TDR may be appreciable, and depends on the number of naïve tests relative to the number of experienced tests. Researchers can examine the effect of ART misclassification on their estimates of the prevalence of TDR if such a bias is suspected.
format Online
Article
Text
id pubmed-3364874
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33648742012-06-05 Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance Castro, Hannah Pillay, Deenan Sabin, Caroline Dunn, David T BMC Med Res Methodol Research Article BACKGROUND: Estimates of the prevalence of transmitted HIV drug resistance (TDR) in a population are derived from resistance tests performed on samples from patients thought to be naïve to antiretroviral treatment (ART). Much of the debate over reliability of estimates of the prevalence of TDR has focused on whether the sample population is representative. However estimates of the prevalence of TDR will also be distorted if some ART-experienced patients are misclassified as ART-naïve. METHODS: The impact of misclassification bias on the rate of TDR was examined. We developed methods to obtain adjusted estimates of the prevalence of TDR for different misclassification rates, and conducted sensitivity analyses of trends in the prevalence of TDR over time using data from the UK HIV Drug Resistance Database. Logistic regression was used to examine trends in the prevalence of TDR over time. RESULTS: The observed rate of TDR was higher than true TDR when misclassification was present and increased as the proportion of misclassification increased. As the number of naïve patients with a resistance test relative to the number of experienced patients with a test increased, the difference between true and observed TDR decreased. The observed prevalence of TDR in the UK reached a peak of 11.3% in 2002 (odds of TDR increased by 1.10 (95% CI 1.02, 1.19, p(linear trend) = 0.02) per year 1997-2002) before decreasing to 7.0% in 2007 (odds of TDR decreased by 0.90 (95% CI 0.87, 0.94, p(linear trend) < 0.001) per year 2002-2007. Trends in adjusted TDR were altered as the misclassification rate increased; the significant downward trend between 2002-2007 was lost when the misclassification increased to over 4%. CONCLUSION: The effect of misclassification of ART on estimates of the prevalence of TDR may be appreciable, and depends on the number of naïve tests relative to the number of experienced tests. Researchers can examine the effect of ART misclassification on their estimates of the prevalence of TDR if such a bias is suspected. BioMed Central 2012-03-14 /pmc/articles/PMC3364874/ /pubmed/22416878 http://dx.doi.org/10.1186/1471-2288-12-30 Text en Copyright ©2012 Castro et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Castro, Hannah
Pillay, Deenan
Sabin, Caroline
Dunn, David T
Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
title Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
title_full Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
title_fullStr Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
title_full_unstemmed Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
title_short Effect of misclassification of antiretroviral treatment status on the prevalence of transmitted HIV-1 drug resistance
title_sort effect of misclassification of antiretroviral treatment status on the prevalence of transmitted hiv-1 drug resistance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3364874/
https://www.ncbi.nlm.nih.gov/pubmed/22416878
http://dx.doi.org/10.1186/1471-2288-12-30
work_keys_str_mv AT castrohannah effectofmisclassificationofantiretroviraltreatmentstatusontheprevalenceoftransmittedhiv1drugresistance
AT pillaydeenan effectofmisclassificationofantiretroviraltreatmentstatusontheprevalenceoftransmittedhiv1drugresistance
AT sabincaroline effectofmisclassificationofantiretroviraltreatmentstatusontheprevalenceoftransmittedhiv1drugresistance
AT dunndavidt effectofmisclassificationofantiretroviraltreatmentstatusontheprevalenceoftransmittedhiv1drugresistance